<?xml version="1.0" encoding="UTF-8"?>
<ref id="B17-antibiotics-09-00217">
 <label>17.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kotani</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Matsumura</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Morita</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Tomida</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Kutsuna</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Nishino</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Yasuike</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Kawamura</surname>
    <given-names>Y.</given-names>
   </name>
  </person-group>
  <article-title>13-(2-Methylbenzyl) Berberine Is a More Potent Inhibitor of MexXY-Dependent Aminoglycoside Resistance than Berberine</article-title>
  <source>Antibiotics</source>
  <year>2019</year>
  <volume>8</volume>
  <elocation-id>212</elocation-id>
  <pub-id pub-id-type="doi">10.3390/antibiotics8040212</pub-id>
  <?supplied-pmid 31698691?>
  <pub-id pub-id-type="pmid">31698691</pub-id>
 </element-citation>
</ref>
